ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.Molecular oncology · 2019Trial
- miR-221/222 Facilitate Pituitary Adenoma Progression Via PHACTR4 Downregulation.Human mutation · 2026Article
- Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.International journal of molecular sciences · 2024Review
- Review article epithelial to mesenchymal transition‑associated microRNAs in breast cancer.Molecular biology reports · 2022Review
- Regulation of microRNA-497 expression in human cancer.Oncology letters · 2021Review
- Contribution of miRNAs in the Pathogenesis of Breast Cancer.Frontiers in oncology · 2021Review
- miR-497-5p Decreased Expression Associated with High-Risk Endometrial Cancer.International journal of molecular sciences · 2020Article
- Regulation of breast cancer metastasis signaling by miRNAs.Cancer metastasis reviews · 2020Review
- Intercalating the Role of MicroRNAs in Cancer: As Enemy or Protector.Asian Pacific journal of cancer prevention : APJCP · 2020Review
- Anti-Angiogenic Effects of Phytochemicals on miRNA Regulating Breast Cancer Progression.Biomolecules · 2020Review
- Review
- miR-15/107 microRNA Gene Group: Characteristics and Functional Implications in Cancer.Frontiers in cell and developmental biology · 2020Review
- Effect of modulation of epithelial-mesenchymal transition regulators Snail1 and Snail2 on cancer cell radiosensitivity by targeting of the cell cycle, cell apoptosis and cell migration/invasion.Oncology letters · 2019Review
- Functional Role of Non-Coding RNAs during Epithelial-To-Mesenchymal Transition.Non-coding RNA · 2018Review
- Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.Journal of translational medicine · 2018Article
- Article
- miR-145 and miR-497 suppress TGF-β-induced epithelial-mesenchymal transition of non-small cell lung cancer by targeting MTDH.Cancer cell international · 2018Article
- MicroRNA‑497 inhibits cellular proliferation, migration and invasion of papillary thyroid cancer by directly targeting AKT3.Molecular medicine reports · 2017Article
- MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC).Cancer biology & therapy · 2017Article
- MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer.British journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial to mesenchymal transition (EMT) is a critical step in the growth and dissemination of malignant diseases, including breast cancer. It is known that microRNAs (miRNAs) play important roles in the regulation of tumor properties in cancers. However, whether miR-497 contributes to EMT in breast cancer cells remains unknown. Our study demonstrated that the expression of miR-497 was significantly decreased in human breast cancer cell lines and breast cancer specimens. In breast cancer cells, EMT was inhibited and promoted by the over-expression as well as depletion of miR-497, respectively. Dual-Luciferase ReporterAassay confirmed that Slug was a direct target of miR-497. The upregulation of miR-497 in breast cancer cells suppressed cell proliferation and induced apoptosis both in vitro and in vivo. Correlation analysis indicated that miR-497 was highly negatively correlated with Slug expression in breast cancer specimens. The knockdown of Slug expression in breast cancer cells significantly suppressed cell proliferation and promoted apoptosis. Our results suggested that the expression of miR-497 is significantly correlated with EMT in breast cancer cells by regulating Slug at the transcriptional as well as translational levels. Therefore, targeting miR-497 may provide a novel strategy for the treatment of breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.